Articles tagged with Pancreatic Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
The use of AI is improving diagnostic accuracy for digestive cancers, but challenges in data sharing and standardization hinder its widespread application. Researchers surveyed recent applications of AI to these deadly cancers, finding that AI can automate complex processes and detect patterns not visible to humans.
A new study found that chemotherapy alters the immune cell landscape in pancreatic cancer, reducing checkpoint molecules and increasing tumor growth. The research suggests that this may lead to resistance to subsequent immunotherapy, highlighting the need for further study on combining chemotherapy with immunotherapy.
Researchers at VCU Massey Cancer Center found that simultaneous activation of Prdm16 and Smad4 proteins slows down pancreatic cancer progression. The study suggests a novel therapeutic approach to tackle this deadly disease.
Researchers explore CEACAM1, CEACAM5, and CEACAM6's pathological significance in cancer biology and immunology. The review highlights their interactions with pathogens and potential avenues for cancer therapy.
A recent study confirms that pancreatic cancer rates are rising faster in women than men, particularly among younger women and Black women. The rate of pancreatic cancer among women under the age of 55 increased by 2.4% compared to men of the same age, highlighting a significant disparity in mortality rates between the sexes.
Researchers detected high levels of hydrogen peroxide in pancreatic cancer cells, which makes it a critical target for cancer treatment and research. The study also showed that cancer-promoting mutations lead to suppressed genetic expression of enzymes breaking down hydrogen peroxide.
The NCI is funding a $587,000 research grant to improve KRAS treatment resistance in pancreatic cancer. Dr. Andrew Waters aims to develop personalized medicine approaches by studying unique resistance mechanisms.
Researchers found that primary cancer tumors have a sluggish conversion of nutrients to usable cellular energy, conserving energy for growth and metastasis. The discovery has vast implications for anti-cancer strategies, directing attention to slow energy metabolism.
Researchers analyzed tumor microenvironment of pancreatic cancer, revealing two major defects that inhibit immune response. The study suggests a new approach using anti-CD137 agonist antibody treatment in combination with anti-PD-1 immunotherapy to activate T cells.
A Phase 3 clinical trial has shown that a four-drug chemotherapy regimen significantly increases overall survival and progression-free survival in patients with stage 4 pancreatic ductal adenocarcinoma. The study's results suggest that this more aggressive treatment approach may be considered for eligible patients.
Researchers at MUSC Hollings Cancer Center discovered the cellular origin of normal pancreatic fibroblasts and cancer-associated fibroblasts, which play a key role in tumor progression. The findings suggest that targeting cancer-associated fibroblasts holds exciting potential for therapeutic benefits.
Researchers at UC San Diego describe how pancreatic cancer stem cells leverage SMARCD3, a protein that normally suppresses tumors, to boost resistance to treatments and drive growth. Deleting SMARCD3 reduces tumor growth and improves survival rates.
Researchers discovered a molecular pathway critical to the initiation of pancreatic tumors, which can contribute to disease resistance and metastasis. Targeting this pathway could limit tumor progression, relapse, and spread by disrupting the interaction between cancer cells and their microenvironment.
Researchers are working to understand the events contributing to pancreatic cancer development by studying gene abnormalities and their effects on the disease. Dr. Krushna Patra's lab is focused on understanding how genetic mutations like GNAS contribute to pancreatic cancer growth.
Scientists have found a way to break down the resistance of mice with neuroendocrine pancreatic cancer to checkpoint blockade immunotherapy. A new drug combination, PD1-IL2v and anti-PD-L1, enhances anti-tumor immunity by stimulating specific T cells and reprogramming macrophages, leading to increased survival rates in tumor-bearing mice.
Researchers at Cima Universidad de Navarra identified LAMC2 as a key gene in pancreatic cancer development. Inhibiting this gene, combined with existing drugs, increases antitumor effect in 3D models.
Researchers at MD Anderson Cancer Center have discovered a novel triple immunotherapy combination targeting checkpoints in T cells and myeloid suppressor cells, improving anti-tumor responses and survival rates in preclinical models of pancreatic cancer. The study found that neutralizing specific immunosuppressive mechanisms dramatical...
Researchers developed predictive models using serum microRNAs to identify patients at risk of requiring early palliative care. The study used serum samples from 178 patients with various types of cancer and found that miRNA-based models had higher accuracy than clinical models in predicting referral to a palliative care unit.
The CodeBreaK 100 trial demonstrates meaningful anticancer activity with sotorasib in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer. The results show an objective response rate of 21.1% and a median time-to-response of 1.5 months.
Scientists at UCSF have engineered T cells to produce a potent anti-cancer cytokine that only activates in tumor cells, eliminating melanoma and pancreatic cancer in mice. The treatment uses IL-2, which supercharges T cells to kill cancer cells while protecting against infection, offering a promising new strategy for fighting hard-to-t...
A new study has identified a potential therapy for metastatic colon cancer by targeting the molecule hyaluronan, which accumulates in tumors and shuts down immune cells that can kill tumor cells. The experimental therapy, hyaluronidase, shrinks tumors and allows immune cells to attack tumor cells.
The study reveals that SETD1A overexpression is associated with poorer disease-free survival in pancreatic cancer patients. Artificially cultured cells showed increased cell growth and migration when SETD1A levels were overexpressed, while knocking down SETD1A expression led to decreased RUVBL1 gene expression.
A new clinical trial has found that chemotherapy before surgery significantly improves 1-year survival rates for patients with borderline resectable pancreatic cancer. The study, led by the University of Liverpool, compared immediate surgery with short-course neoadjuvant therapy and found a significant survival benefit.
A nationwide retrospective study showed that adjuvant chemotherapy after neo-adjuvant chemotherapy and surgery significantly improved overall survival in patients with pancreatic adenocarcinoma, regardless of lymph node status or resection margins. The study included nearly 900 patients and was published in JAMA Oncology.
Researchers visualized the (pro)renin receptor's protein binding site and found hand-shaped grooves allowing for multiple protein binding. The study provides new insight into disease pathogenesis and aids in exploring novel treatments.
Researchers developed a small molecule inhibitor that successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer. The drug, MRTX1133, not only targets cancer cells but also cooperates with the immune system to produce a durable response to treatment.
Researchers at VCU Massey Cancer Center discovered the inactivation of NF1 as a potential genetic driver for pancreatic cancer. The study suggests that targeting NF1 could create vulnerabilities for therapeutic advantage in mutant KRAS-bearing tumors.
Researchers at University of Pittsburgh have designed novel nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy, shrinking tumors in mouse models of colon and pancreatic cancer. The therapy silences a gene involved in immunosuppression by blocking Xkr8 protein distribution on the cell membrane.
A recent study found that MRI-guided adaptive radiation therapy, also known as SMART, has shown promising safety and patient outcomes data for treating locally advanced and borderline resectable pancreatic cancer. The study, led by Henry Ford Health, reported no incidence of acute grade 3 or higher gastrointestinal toxicity, with preli...
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
A new study by Cedars-Sinai investigators has identified risk factors for developing diabetes in people with chronic pancreatitis, including smoking and being overweight. The findings suggest that models can be built to predict diabetes risk, allowing clinicians to connect patients with weight loss or smoking cessation programs.
Researchers found that a new drug inhibiting GRP78 effectively reduces SARS-CoV-2 replication in human lung cells. The drug also shows potential in treating certain types of cancer by suppressing mutant KRAS proteins.
A specialized triage algorithm, ROCA test, enables earlier stage diagnosis in women deferring preventive surgery, saving NHS costs. The approach results in fewer major surgical interventions and lower risk of wider disease spread.
In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
Researchers at Duke University have developed a novel treatment that combines internal radiation and chemotherapy to eliminate tumors in 80% of mice with pancreatic cancer. The approach uses a gel-like depot implanted with radioactive iodine-131, which deposits beta radiation directly into the tumor without affecting surrounding tissue.
Scientists at the University of Florida have identified two small molecules that inhibit precancerous cell progression and reverse a key process involved in pancreatic cancer progression. This discovery could lead to earlier treatments and improved survival rates for patients with pancreatic cancer.
Virginia Tech researchers found that a common oral bacterium, Fusobacterium nucleatum, drives pancreatic cancer cell proliferation and migration. The bacterium can infect normal pancreatic tissue cells, stimulating nearby cancer cells to grow and spread rapidly.
Researchers developed an antibody-based treatment that targets cadherins on circulating tumor cells, eliminating them in mouse models of breast and pancreatic cancer. The therapy shows promise in preventing cancer metastasis, a leading cause of cancer-related deaths.
Scientists at The Wistar Institute have discovered a correlation between mitochondrial dysfunction and aggressive pancreatic cancer. An 11-gene signature indicative of mitochondrial reprogramming in tumors has been identified, which correlates with poor patient outcomes and treatment resistance.
Researchers propose an optical imaging system for real-time hypoxia imaging in cancer treatment. The technique utilizes protoporphyrin IX to enhance contrast between tumors and healthy tissues, allowing for more effective surgical removal.
A study found that over a third (36%) of post-imaging pancreatic cancer cases were potentially avoidable, highlighting poor detection rates. Researchers analyzed patient records to develop an algorithm to categorize missed cases and identify the most likely explanation for why they were missed.
Researchers from Rutgers Cancer Institute have identified specific microorganisms associated with inflammation and poor survival in pancreatic tumors. These microbial signatures can be used as new targets for earlier diagnosis or treatment of the fourth leading cause of cancer death.
Researchers developed a novel organoid model to study pancreatic cancer cells' growth and arrangement. The model provides insight into the three-dimensional structure of tumors, enabling tracking of individual growth stages, cell divisions, and gene expression patterns.
A new study found that the organization of different types of immune cells within pancreatic tumors is associated with patient outcomes. Immune cells called IL-10+ myelomonocytes tend to be located close to specific T cell types, which may affect cancer treatment responses.
Researchers at UNC Lineberger Comprehensive Cancer Center have found a way to overcome barriers limiting cancer immunotherapies. They discovered that activating the STING protein can increase regulatory B cells, which suppress anti-cancer immunity.
A new genetic test called PancreaSeq accurately classifies pancreatic cysts as potentially cancerous or benign, improving the accuracy of diagnoses compared to current guidelines. The test distinguishes between different types of cysts with higher accuracy than traditional forms of surveillance and current pancreatic cyst guidelines.
Researchers found that the quality and mix of collagen in pancreatic ductal adenocarcinoma tumors affects prognosis. Patients with tumors containing cleaved Collagen I experienced poor survival prospects, while those with non-cleaved Collagen I had better outcomes.
Cleveland researchers reveal a new strategy to prevent blood clots by targeting overactive neutrophils, reducing clotting risk while minimizing bleeding risk. The findings may be especially impactful for cancer patients who experience blood clot complications.
Researchers at Mayo Clinic Comprehensive Cancer Center have identified a gene marker that may lead to more effective precision treatment for pancreatic ductal adenocarcinoma. The protein METTL16 is correlated with accumulated DNA damage and suppresses DNA repair, suggesting it as a potential biomarker for PARPi treatment.
Researchers found that stress granules are abundant in obesity-related pancreatic cancer and blocking their formation stops cancer growth in animals. The study reveals a potential new direction for developing cancer therapy by targeting stress granule formation.
A new AI tool has been developed to detect pancreatic cancer on CT scans with high accuracy, achieving 90% sensitivity and 96% specificity. The tool's performance is comparable to that of radiologists, offering a promising supplement for early detection and improved treatment outcomes.
Researchers at California NanoSystems Institute developed a nanocarrier that delivers a combination therapy to pancreatic tumors using irinotecan and 3M-052, resulting in improved treatment outcomes and reduced side effects. The simultaneous delivery of the two drugs outperformed separate treatments in mouse models.
In a Phase I/II trial, selpercatinib demonstrated a 44% objective response rate across multiple tumor types, including pancreatic and colorectal cancers. The study found responses regardless of cancer type or prior treatment history, confirming RET fusions as a tissue-agnostic target.
Researchers at Mayo Clinic Comprehensive Cancer Center found that metabolic imaging, combined with traditional treatment response assessment methods, can provide critical information to guide therapy for pancreatic cancer patients. The use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant pr...
Champalimaud Foundation researchers have developed a new biomarker, IgG-positive EVs, to assess treatment response in pancreatic cancer patients. These extracellular vesicles increase during disease progression and decrease in response to therapy, offering a more reliable tool for evaluating tumour status.
A UCSF-led team reveals that tumor immune microenvironments play a crucial role in the progression of pancreatic cysts to pancreatic cancer. The study suggests that therapies targeting regulatory T cells and myeloid-derived suppressor cells could inhibit malignant progression and treat high-risk disease.
Researchers at UVA have discovered the mechanism behind gene regulation during organ development, shedding light on how genetic material interacts with transcription factors to create different cell types. The study's findings could offer insights into the initiation of certain cancers and inspire new therapeutic development.
A study has revealed two key transition points in the development of pancreatic cancer, shedding light on treatment resistance and possible new therapies. The research provides insights into how normal cells become precancerous and cancerous, as well as a new strategy for checkpoint immunotherapy.